abacavir / Generic mfg. - LARVOL DELTA

Kidney Disease in HIV Infected Children on HAART in Nigeria. (PubMed, Afr Health Sci) - "A statistically significant association was observed between renal disease and high viral load, as well as the use of an abacavir or tenofovir-based regimen. These findings emphasize the importance of regular kidney function monitoring and tailored antiretroviral therapy selection in the management of HIV-infected children."

Journal • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Renal Disease

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. (PubMed, Elife) - P2 | "Twenty HIV-infected adults, who had received a triple ART consisting of 50 mg DTG/600 mg abacavir/300 mg lamivudine pre-intensification and had been suppressed on ART for at least 2 years, were enrolled in a phase 2 randomized clinical trial (https://clinicaltrials.gov/ identifier: NCT05351684). Our results strongly suggest that the pre-intensification ART regimen was not completely suppressive. If confirmed in larger clinical trials, these results could have an impact on the clinical management of PWH and HIV curative strategies."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8

Update on pharmacogenetics in pediatrics. (PubMed, An Pediatr (Engl Ed)) - "Drug-gene pairs with greater use in pediatrics are presented in more detail, such as proton pump inhibitors and CYP2C19, Abacavir, allopurinol, carbamazepine, oxcarbazepine, and phenytoin with HLA-A and HLA-B genes, voriconazole and CYP2C19, tacrolimus and CYP3A5, aminoglycosides and MT-RNR1, thiopurines and TMPT/NUDT15, or atomoxetine and CYP2D6. Despite current limitations, the use of pharmacogenetics in pediatrics can and should be implemented in those cases where regulatory agencies and/or scientific societies recommend it."

Biomarker • Journal • Pediatrics • CYP2C19 • CYP3A5 • HLA-B • NUDT15

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice. (PubMed, Allergy) - "In vivo upregulation of HLA expression modulates the balance between drug-specific and regulatory T cells, thereby promoting optimal pDC expansion and enhancing IFN-α production, which counteracts Treg-mediated ABC tolerance. IFN-γ secretion by drug-specific CD8+ T-cells promoted APC and effector T-cell function that led to the development of ABC-associated hypersensitivity reactions in immunocompetent HLA Tg mice."

Journal • Preclinical • Immunology • CD8 • HLA-B • IFNA1 • IFNG

Eco-friendly nanoscale recognition: a MIP-based electrochemical sensor for selective determination of abacavir in pharmaceutical and serum samples. (PubMed, Anal Bioanal Chem) - "Detailed selectivity tests validated the sensor's high affinity to ABC in the presence of structurally and pharmaceutically related drugs (lamivudine, zidovudine, tenofovir, etc.). Additionally, the Analytical GREEnness Metric Approach (AGREE), the Analytical Greenness Metric for Sample Preparation (AGREEprep), the Blue Applicability Grade Index (BAGI), and the Analytical Greenness Assessment Tool for Molecularly Imprinted Polymer Synthesis (AGREEMIP) tools were utilized to assess sensor's green profile. The ACR-ABC/MWCNT-NH2@MIP/GCE sensor demonstrated its potential to provide a selective, reliable, low-cost, and efficient analytical tool for ABC analysis."

Journal

Comparison of different methods for the detection of HLA-B* 57:01 allele in people living with HIV in Eastern Uttar Pradesh, India. (PubMed, BMC Infect Dis) - "Nested (two-step) and HCP5 gene PCR (single-step) are simple, rapid and cost-effective methods for HLA-B*57:01 allele detection and either can be adapted in the ART centre located in resource-poor settings."

Clinical • Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • HLA-B

Cardiovascular disease in people living with HIV in Malaysia: A competing risks cohort analysis. (PubMed, HIV Med) - "CVD risk among PLHIV is non-negligible. Integrating CVD prevention into HIV care is critical, particularly for older adults and those on specific ART regimens."

Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. (PubMed, medRxiv) - "Twenty HIV-infected adults, who had received a triple ART consisting of 50mg DTG/600 mg abacavir/300 mg lamivudine pre-intensification and had been suppressed on ART for at least two years, were enrolled in a phase 2 randomized clinical trial. Our results strongly suggest that the pre-intensification ART regimen was not completely suppressive. If confirmed in larger clinical trials, these results could have an impact on the clinical management of PWH and HIV curative strategies."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8

High-throughput screening for class I peptide MHC binding via yeast surface display. (PubMed, Proc Natl Acad Sci U S A) - "Through this, we isolate unique biological phenomena such as alteration of the peptide presentation of HLA-B57 via interaction with the antiviral small molecule abacavir. We apply this approach to multiple pathogen proteomes (Mycobacterium tuberculosis Type VII secretion substrates, SARS-CoV-2, Dengue, and Zika) to create a comprehensive list of potential T cell antigens. Altogether, this platform acts as a flexible tool to generate large unbiased datasets for class I peptide binding at a speed and scale competitive with the biological systems they represent."

Journal • Dengue Fever • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Targeted cellular depletion in an immune-liver-on-a-chip platform elucidates cell-type-specific heterogeneity in drug-induced hepatotoxicity. (PubMed, Commun Biol) - "We applied the targeted depletion strategy to resolve cell population-specific contributions to hepatotoxic outcomes using four mechanistically diverse compounds: acetaminophen, ethinyl estradiol, sulfamethoxazole, and abacavir. The immune-dependent toxicity resolution was further validated using a known immune-mediated drug-induced liver injury drug, allopurinol. Overall, this study establishes a targeted cell depletion strategy integrated within an immunocompetent liver-on-a-chip platform, enabling rapid identification of hepatotoxic determinants, and represents a significant advancement in predictive toxicology systems, while providing strategic insights for subsequent pathway analysis."

Heterogeneity • Journal • Hepatology • Liver Failure

Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression (ISPOR-EU 2025) - "Compared to B/F/TAF, ML-NMR results showed significantly greater decline in eGFR from baseline with dolutegravir/lamivudine (DTG/3TC) (mean difference [95% CrI]: -4.40 [-5.30, -3.51]) and DTG/abacavir/3TC (-3.60 [-5.74, -1.50]); change in eGFR was similar to DTG+F/TAF (-1.19 [-3.35, 1.06]). B/F/TAF demonstrated a more favorable renal safety profile compared to tenofovir-sparing DTG-based regimens, with similar all-cause discontinuation rates compared to other recommended ARTs, including DTG/3TC, and the investigational NRTI-sparing doravirine/islatravir. These findings support B/F/TAF as a renally safe and well-tolerated treatment option for TE PWH."

Clinical • Review • Human Immunodeficiency Virus • Infectious Disease

Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela. (PubMed, AIDS Res Ther) - "A high viral suppression rate of over 90% was documented for all DTG-based regimens, with no significant difference found between the main regimen (DTG/3TC/TDF) and its alternatives: DTG/emtricitabine/tenofovir alafenamide (TAF), abacavir/3TC + DTG and, DTG/3TC. Overall, almost all switches (97.1%) were made toward DTG/FTC/TAF. Osteoporosis was the main reason for switching treatments (80.1%)."

Journal • Human Immunodeficiency Virus • Infectious Disease • Osteoporosis • Rheumatology

Guidelines From the French-Speaking Society for Histocompatibility and Immunogenetics (SFHI) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics. (PubMed, HLA) - "Well-established associations include HLA-DQB1*02/DQA1*05 (DQ2) and HLA-DQB1*03:02/DQA1*05 (DQ8) with celiac disease, HLA-B*27 with spondyloarthritis, HLA-DQB1*06:02 with type 1 narcolepsy, HLA-A*29 with Birdshot chorioretinopathy and several pharmacogenetic risk alleles such as HLA-B*57:01 (abacavir), HLA-B*15:02 and HLA-A*31:01 (carbamazepine) and HLA-B*58:01 (allopurinol). In immunotherapy, the efficacy of tebentafusp has been shown to depend on HLA-A*02:01 positivity...Interpretation should be conducted by qualified medical biologists, integrating clinical context, allelic diversity and recent technological advances, particularly next-generation sequencing. HLA genotyping represents a valuable tool in diagnosis and risk assessment, with increasing importance in the era of personalised medicine."

Biomarker • Clinical guideline • Harmonization • IO biomarker • Journal • Review • Ankylosing Spondylitis • Celiac Disease • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Narcolepsy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Seronegative Spondyloarthropathies • Sleep Disorder • Spondylarthritis • Thrombocytopenia • Thrombocytopenic Purpura • Uveitis • HLA-A • HLA-B • HLA-DQB1

Real-World Persistence in Adults with HIV and Mental Health or Substance Use Disorders After Restarting Antiretroviral Therapy in the United States. (PubMed, Adv Ther) - "For PWH-MHD/SUD who restarted ART after a treatment interruption, B/F/TAF was associated with longer persistence and the lowest risk of switch compared with other guideline-recommended therapies."

Journal • Real-world evidence • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Psychiatry

Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV Failing on First-line Antiretroviral Therapy in Uganda. (PubMed, J Acquir Immune Defic Syndr) - "Low rates of DTG resistance among Ugandan CLHIV failing first-line DTG-based ART regimens underscores the durability of DTG. Lack of difference in ABC resistance across all regimens supports maintaining an ABC backbone for CLHIV <30kg when transitioning to a DTG-based regimen despite virologic failure."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Preferential Recognition of Drug-Induced Altered Self-Presentation on Tumor Cells, but Not Host Cells, by CD8+ T Cells for Eliciting Anti-Tumor Immunity. (PubMed, Biol Pharm Bull) - "Although the anti-human immunodeficiency virus drug abacavir (ABC) increases the tumor immunogenicity and induces CD8+ T cell anti-tumor immune responses in mice inoculated with tumor cells ectopically expressing the human leukocyte antigen (HLA)-B*57:01, whether such anti-tumor immunity is also triggered in hosts with high HLA-B*57:01 expression levels remain unclear...Moreover, ABC did not increase the effector CD8+ T cell proportions in the tumor-draining lymph nodes of B*57:01-Tg mice. Overall, CD8+ T cells preferentially recognized the ABC-induced altered self-antigen-presenting HLA-B*57:01-expressing tumor cells, but not host cells, to elicit anti-tumor immunity."

IO biomarker • Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology • CD8 • HLA-B • IFNG

Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study. (PubMed, Ther Adv Infect Dis) - P=N/A | "Men, individuals previously receiving abacavir/3TC/DTG, and those with better daily comfort and perceived treatment efficacy were less likely to stop treatment. Attention should be maintained on the reasons for treatment discontinuation, especially among women. Patient-Reported Outcomes HV BItherapy (PROBI) was registered as number NCT04788784 on https://clinicaltrials.gov/study/NCT04788784?term=PROBI&rank=2."

Journal • Human Immunodeficiency Virus • Infectious Disease

Outcomes of HIV-Exposed Uninfected Children Born to HIV-Positive Mothers at Bichat-Claude Bernard Hospital: The ENIVIH Study (EACS 2025) - "Among children with events, in utero ARV exposures included zidovudine (4.1%), emtricitabine (46.2%), darunavir (35.9%), and abacavir (4.8%). These frequencies appear higher than those typically reported in the general pediatric population. The findings highlight the importance of long-term follow-up and integrated medical and social for HEU children."

Clinical • Human Immunodeficiency Virus • Infectious Disease

LDL Target Achievement in people with HIV Over 40: Impact of Updated EACS Guidelines (EACS 2025) - "Use of abacavir- (6.6 vs 3.3%, p<0.001 ) and PI-based (13.6 vs 11.7, p=0.15) ART regimens declined from period 1 to period 2...LDL target achievement improved significantly for Step 1 (21% to 25%, p<0,05 ) and marginally for Step 2 (5.2% to 5.9%, p=0.45) (Figure 2). Conclusions : Despite updated EACS guidelines and increased lipid-lowering therapy, LDL target attainment remains suboptimal in our PWH cohort."

Human Immunodeficiency Virus • Infectious Disease

Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis (EACS 2025) - "Purpose : In Japan, the dolutegravir/lamivudine (DTG/3TC) single-pill combination is more expensive than dolutegravir plus generic ABC/3TC, which contains abacavir (ABC) with potential cardiovascular risks as elucidated by the REPRIEVE trial. Therefore, the DTG/3TC single-pill regimen can be considered cost-effective in this setting. These findings highlight the need to balance financial benefits against clinical risks and may not extrapolate directly to other countries where drug cost differentials vary and background cardiovascular risks differ."

Cost effectiveness • HEOR • Infectious Disease • CD4

Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice. (PubMed, Int J STD AIDS) - "All people with HIV-1 receiving DTG-containing ART regimens-combined with rilpivirine (RPV) or lamivudine (3TC) for 2DRs, or with tenofovir (TAF or TDF) and emtricitabine (FTC), or abacavir (ABC) and FTC for 3DRs-were included. However, the study's retrospective nature and center-specific characteristics may limit generalizability. More real-world data are warranted to confirm these results."

Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease • CD4

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients (clinicaltrials.gov) - P4 | N=19 | Completed | Sponsor: Fundacion Clinic per a la Recerca Biomédica | Unknown status ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • Solid Organ Transplantation • Transplantation

EVALUATION OF THE QUALITY OF THE FIXED-DOSE TRIPLE COMBINATION DISPERSIBLE TABLET FOR HIV-POSITIVE PAEDIATRIC POPULATION AFTER THE CONTINUOUS DIRECT COMPRESSION AND BATCH MANUFACTURING TECHNIQUES. (PubMed, Eur J Pharm Sci) - "FDC dispersible tablets were successfully manufactured with CDC and batch methods. Moreover, the product integrity results were similar for both the production technologies. However, the formulation and pre-blends require further optimization particularly for poorly flowable active pharmaceutical ingredients."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Effectiveness and safety of tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe. (PubMed, Int J Antimicrob Agents) - "Virological outcomes were similar across drugs. Rates of any grade laboratory events were highest on TAF, driven by higher rates of lipid events. As TAF uptake increases, studies with long-term follow-up are required."

Journal • Human Immunodeficiency Virus • Infectious Disease • Renal Calculi